This summer kicked off a new era of innovation at LabCentral. Thanks to a Sector Spark grant from the Massachusetts Technology Collective, we are building out the AI BioHub at our flagship lab space in Kendall Square. This dedicated lab suite is being outfitted with new, advanced instrumentation that will aid our resident biotech startups in processing samples efficiently and generating data to validate their artificial intelligence (AI) and machine learning (ML) models.
In addition to the infrastructure upgrades, LabCentral is running our first-ever AI BioHub Accelerator Program cohort with our partners at C10 Labs, a venture studio fund supporting AI-first startups. With the combined expertise of our two organizations, we are perfectly placed to provide specialized programming for entrepreneurs working at the intersection of life sciences and AI. Cohort members not only get access to shared lab space and equipment at LabCentral’s state-of-the-art facility, but they also participate in an intensive, multi-week program focused on learning and development. This includes participation in regular “Tech Talks,” workshops, and individualized mentorship.
After spending the past several weeks diving deeper into generative AI, fine-tuning AI experimentation, and exploring prebuilt models, the first cohort is nearing its close. The teams have completed a hackathon and will soon be preparing for a startup showcase, the culmination of their work in the AI BioHub Accelerator Program.
LabCentral and C10 are excited to introduce the 15 startups participating in the first cohort and their innovative approaches to solving problems for human health, using AI and ML models.
- Celvion Therapeutics: Celvion is advancing AI-designed T cell therapies that integrate dual TCR and CAR systems to address tumor heterogeneity, with a primary focus on solid tumors. Cell engineering is driven by two proprietary computational platforms—one dedicated to TCR optimization and the other to identifying synergistic targets for combined CAR and TCR functionality.
- Elastro: A Harvard/MGH spinout, Elastro is building a next-gen brain-computer interface that engages deep brain regions and uses AI to actively modulate brain signals, not just record them.
- Eternity: Eternity is building the first multimodal foundation model for the human “second genome” — the gut microbiome — to predict how gut bacteria interact with drugs or food compounds, transforming the gut from a black box into a controllable variable. Powered by its own unique data generation pipeline, it delivers population-scale insights in hours, enabling safer, more effective products before clinical trials begin.
- Homara AI: Homara AI transforms raw multi-omics data into insights—automating everything from cleaning and QC to full analysis, so biopharma teams can accelerate discovery and validation 10× faster and 80% cheaper.
- KiraGen Bio: KiraGen develops multiplex-edited CAR-T therapies using AI-designed knockout combinations that block tumor suppression pathways, starting with GBM, to enable durable treatment across solid cancers.
- LymeAlert: LymeAlert offers the first at-home tick test for Lyme disease with a paired AI-driven app that maps exposure hotspots using computer vision and federated learning.
- MultiOmics: MultiOmics is building an AI-native platform to discover and validate plasma biomarkers for cancer and chronic disease, starting with breast cancer.
- Noara Therapeutics: Noara is developing next-gen RNA therapeutics using AI and a proprietary high-throughput screening platform to treat chronic diseases.
- Neoclease: Neoclease builds AI-designed gene editors custom-fit to individual genes, unlocking targets CRISPR can’t touch. Our lead program is a first-in-class LRRK2 knockout aimed at the root drivers of Parkinson’s disease progression.
- Nervoid: Nervoid uses AI-driven discovery to develop new therapies that target the dopaminergic system and reduce opioid addiction and drug-seeking behavior.
- Oralics: Oralics enables rapid, AI-powered detection of oral microbiome signatures via low-cost digital imaging—eliminating the need for sequencing in clinical and field settings.
- RegulaBio: Regula Bio combines patient-derived multiomics with AI to map chronic disease pathways and identify therapeutic regulators that restore cellular health.
- Riboway Therapeutics: Riboway decodes RNA biology with AI to precisely control protein function, making previously “undruggable” targets accessible through RNA-targeted therapeutics.
- Semmelweis Labs: Semmelweis Labs prevents disease outbreaks in livestock using AI-powered aerosol sampling, helping farmers act before symptoms emerge and safeguarding food systems.
- SequestBio: SequestBio uses an AI platform to predict cancer metastasis and design personalized therapies that reshape the tumor microenvironment for better patient outcomes.
As we approach the conclusion of the first AI BioHub Accelerator cohort, we look forward to celebrating the work these 15 companies have done throughout the program and finding ways to showcase their work and progress. We will review the program and look for opportunities to improve and evolve as we prepare for the 2026 cohort.
At LabCentral, we are committed to continually evolving our infrastructure and community to best support the next generation of biotech startups. Integrating AI capabilities into our ecosystem is a natural and necessary part of that vision.
In 2026, LabCentral and C10 Labs will be launching a second cohort of the accelerator program. We will share more information on applications and program specifics as we get closer.
